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Background. With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, drug–drug inter-
actions (DDIs) emerged as significant challenge. Since then, HCV therapy and the infected population have rapidly changed. So far, 
very limited data are available regarding the clinical relevance of DDIs when using most modern DAA regimens. We aimed to assess 
how the importance of DDIs has evolved over time.
Methods. From January 2014 to July 2018, 668 consecutive HCV patients were evaluated for their outpatient medication and 
assessed for DDIs with DAAs. Different time periods were defined based on market approval of key DAAs: A (01/2014–11/2014), B 
(11/2014–08/2016), and C (08/2016–07/2018).
Results. The frequency of patients with real-world DDIs was highest in period B (A: 37.1%, B: 49.6%, C: 38.8%). The recently 
approved DAAs (period C) theoretically showed a lower DDI risk profile. However, real-world DDIs were still comparable to period 
A, as HCV patients’ characteristics changed (eg, age ≥75 years: A: 3.1%, B: 9.8%, C: 5.6%; polypharmacy/patients with ≥8 drugs: 
A: 11.1%, B: 15.2%, C: 17.2%). Furthermore, although DDIs via CYP 3A4 became less important for some modern regimens, other 
mechanisms like an altered pH value in the stomach, causing reduced bioavailability, evolved. Relevant DDIs most frequently oc-
curred with proton pump inhibitors, metamizole, statins, and carvedilol.
Conclusions. DDIs during antiviral treatment still affect about 40% of HCV patients. The lower DDI potential of modern DAA 
regimens is partly counteracted by changing patient characteristics. Therefore, DDIs should not be underestimated.
Keywords.  direct-acting antivirals (DAAs); drug–drug interactions (DDIs); hepatitis C virus (HCV) infection; patient charac-
teristics; polypharmacy.
In 2015, ~71 million people worldwide suffered from chronic 
hepatitis C virus (HCV) infection [1]. Currently the World 
Health Organization (WHO) is calling for a reduction of new 
infections by 90% and mortality by 65% by 2030, with the ul-
timate aim of HCV elimination [1]. This ambitious goal is 
driven by the tremendous improvements in HCV therapy that 
have been achieved due to the development of direct-acting 
antivirals (DAAs).
The first DAAs, the protease inhibitors (PIs) boceprevir 
(BOC) and telaprevir (TVR), were approved in 2011 but had 
several limitations. Both PIs were accompanied by considerable 
adverse events like anemia or skin rash; their usage was mainly 
restricted to HCV genotype 1, and their efficacy was rather 
limited [2–5]. Combination with pegylated interferon α 
(PEG-IFN α) was still required [6]. Thus, a significant propor-
tion of patients (eg, those with advanced cirrhosis, significant 
comorbidities) were not eligible for therapy, and many of those 
with mild disease chose to defer treatment [7–9]. Furthermore, 
drug–drug interactions (DDIs) emerged as a new important 
challenge [10, 11]. BOC and TVR are substrates and inhibi-
tors of P-glycoprotein (P-gp) and cytochrome P450 (CYP) 3A4 
pathways that are frequently involved in DDIs [10].
In various fields of medicine, DDIs are a common but often 
neglected cause of drug-associated adverse events. In general, 
~1% of all hospital admissions are caused by DDIs, with a 
higher risk in patients on polypharmacy [12, 13].
Since 2011, several new DAAs have been developed. Approval of 
the polymerase inhibitor sofosbuvir (SOF) in January 2014 allowed for 
IFN-free therapy, which facilitated treatment eligibility [14]. In 2014–
2015, the first fixed-dose combination of SOF and the NS5A inhibitor 
ledipasvir (LDV) was approved, as well as the combination of omb-
itasvir + paritaprevir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), 
which increased the rates of sustained virological response (SVR) 
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[15–19]. However, DDIs still had to be considered, especially in the 
ritonavir-based regimen [20–23]. When looking at ritonavir in par-
ticular, a strong inhibition of CYP 3A4 affects the metabolism of var-
ious concomitant medications, leading to multiple clinical relevant 
DDIs. Finally, in 2016–2017, velpatasvir + sofosbuvir (VEL/SOF), 
elbasvir + grazoprevir (ELB/GRZ), glecaprevir + pibrentasvir (GLE/
PIB), and velpatasvir + sofosbuvir + voxilaprevir (VEL/SOF/VOX) 
were marketed, which resulted in further improvements such as 
pangenotypic efficacy and the re-treatment of DAA failures [24–30].
Until now, almost all previous limitations of HCV treat-
ment have been overcome. Currently available DAA regimens 
achieve SVR in >98% of patients and are very well tolerated 
[24–30]. It is widely believed that with today’s treatment op-
tions the risk for DDI via, for example, CYP 3A4 or P-gp is sig-
nificantly lower as compared with previously used regimens. 
However, it has to be considered that other interaction mechan-
isms might have become relevant [31]. Furthermore, as almost 
all HCV patients are now eligible for the pangenotypic regimens 
and HCV elimination has been declared as the ultimate goal, 
it is to be expected that the diversity of HCV patients who re-
ceive antiviral treatment has increased over the last years. This 
includes patients with significant comorbidities, older age, and 
polypharmacy [21]. Although some studies have investigated 
DDIs with older DAA regimens in the past, almost no data are 
available regarding the relevance and most important mech-
anisms of DDIs when using the most modern DAA regimens. 
Furthermore, no study has addressed how the changes in the 
HCV-infected and -treated populations, which were accom-
panied by rapid improvements in HCV therapy, affected the 
risk for significant DDIs.
The aim of this work was to analyze the relevance and most 
frequent mechanisms of DDIs in the rapidly changing field of 
HCV therapy. A particular focus was put on the current situ-
ation using the most modern DAA regimens in the remaining 
HCV population.
METHODS
Cohort
Overall, 668 consecutive patients with chronic HCV infection 
who were treated with a DAA regimen at the hepatitis outpatient 
clinic of Hannover Medical School from January 2014 to July 
2018 were included. To analyze the changing epidemiology and 
frequency of potential DDIs within the evolving field of DAA 
therapies, 3 different time periods were defined based on the 
approval of key DAA regimens that significantly changed HCV 
therapy at our center: (A) January 22, 2014 (first patient treated 
with SOF, and therefore IFN-free therapy became available), to 
November 28, 2014; (B) November 29, 2014 (first patient treated 
with LDV/SOF or OBV/PTV/r ± DSV, and therefore fixed-dose 
regimens became available), to August 14, 2016; and (C) August 
15, 2016 (first patient treated with velpatasvir [VEL], elbasvir/
grazoprevir [ELB/GRZ], or glecaprevir/pibrentasvir [GLE/
PIB], and therefore pangenotypic therapies as well as highly ef-
fective re-treatment options became available), to July 31, 2018.
Assessment of Baseline Characteristics and Patients’ Regular Outpatient 
Medications
Laboratory testing for albumin, bilirubin, and quick/interna-
tional normalized ratio (INR) was performed due to standard 
procedures at Hannover Medical School. HCV genotype setting 
was performed with the INNO-LiPA by Innogenetics according 
to the manufacturer’s instructions. Liver cirrhosis in patients 
was calculated using transient elastography. The applied cutoff 
value for cirrhosis was >13 kPa [32]. In case of failed transient 
elastography, additional clinical and laboratory parameters (ie, 
albumin, bilirubin, quick, INR, sonographic proof of ascites, 
and stage of encephalopathy) were used to determine the stage 
of liver cirrhosis.
Before treatment, all patients included in this retrospec-
tive analysis were routinely asked for all their regular outpa-
tient medication. All types of medication were documented, 
including over-the-counter drugs and other nonprescription 
drugs, herbal drugs, and nutritional supplements. Due to the 
fact that herbal drugs and nutritional supplements more often 
contain several (active) ingredients, these were only counted 
as 1 medication. In case of other combination preparations, 
for example, sitagliptin/metformin, each active ingredient was 
counted separately. In some cases, the regular outpatient med-
ication was modified before treatment due to the risk of DDI 
with the selected DAA therapy. Concerning this matter, we in-
cluded the unmodified outpatient medication in the analysis.
Evaluation of Drug–Drug Interactions
DDIs were evaluated using www.hep-druginteractions.org (as of 
July 2019). In case of missing information, a clinical pharmacist 
and clinical pharmacologist were consulted. Pharmacokinetic 
and pharmacodynamic interactions between the antiviral sub-
stances and the regular outpatient medications were considered. 
Interactions were classified into 4 different categories: (1) no 
interaction expected, (2) potential weak interaction (additional 
action unlikely to be required), (3) potential significant interac-
tion (additional monitoring, dose adjustment or therapy adjust-
ment required), and (4) do not coadminister/contraindicated.
Interaction mechanisms with the DAA regimens were identi-
fied and analyzed. Information about the mechanisms of inter-
action was provided by the latest prescribing information and 
www.hep-druginteractions.org (as of November 2019).
Analysis of Drug–Drug Interactions
The relevance of DDIs was analyzed in 2 different scenarios:
 1. Potential of different antiviral medications for DDIs with the 
regular outpatient medication
Drug–Drug Interactions in HCV Therapy • ofid • 3
Potential DDIs were assessed between all regular outpatient 
medications used in the total cohort and each individual an-
tiviral that was available for the treatment of HCV infection in 
the last decade. Administration of a fixed-dose combination was 
analyzed as a single medication. The following DAAs were as-
sessed: boceprevir (BOC), telaprevir (TVR), daclatasvir (DAC), 
simeprevir (SIM), sofosbuvir (SOF), ombitasvir + paritapre
vir + ritonavir ± dasabuvir (OBV/PTV/r ± DSV), ledipasvir 
(LDV) + sofosbuvir (SOF), glecaprevir (GLE) + pibrentasvir 
(PIB), elbasvir (ELB) + grazoprevir (GRZ), velpatasvir 
(VEL) + sofosbuvir (SOF) ± voxilaprevir (VOX). DAAs already 
withdrawn from the market (BOC, TVR, DAC, and SIM) were 
only analyzed to compare the frequencies of potential DDIs with 
the more modern regimens. In addition, DDIs were analyzed 
for pegylated interferon α (PEG-IFN α) and ribavirin (RBV).
 2. Real-world incidence of DDIs due to antiviral treatment
DDIs were assessed between the actual regular outpatient med-
ication and the actually used antiviral regimen in the respective 
patient. If >1 interaction per patient was identified, the more 
severe interaction category was chosen.
Statistics
The data are reported as absolute numbers, means, medians, 
percentages, and ranges, always clearly labeled. Statistical anal-
ysis was conducted using the chi-square test, f test, t test, and 
calculation of the relative risk. P values <.05 were considered 
statistically significant. Microsoft Excel (2010) was used for 
data collection and quantification, and IBM SPSS (version 
25) was used for further analysis.
Ethics
This retrospective analysis was performed according to 
the principles of good clinical practice and the declaration 
of Helsinki and approved by the local ethics committee of 
Hannover Medical School (Nr. 8132_BO_K_2018). All patients 
gave written informed consent.
RESULTS
Changing Epidemiology of the Treated HCV Population Since 2014
Overall, 668 patients were included in the analysis; 45.1% were 
female, and 45.1% had liver cirrhosis. The median number of 
drugs in the regular outpatient medication (range) was 3 (0–19). 
The mean age (range) was 55.5 (18–85) years. Furthermore, 44 
patients (6.6%) were ≥75  years old. The mean age of the pa-
tients fluctuated over time, with a lower mean age of the pa-
tients in the most recent period (mean age in years: A: 55.3, B: 
58.2, C: 52.9; A–B P = .011, B–C P < .001, and A–C P = .033). 
However, the proportion of patients aged ≥75 years increased 
from the first to the third observation period (A: 3.1%, B: 9.8%, 
C: 5.6%; A–B P = .010, B–C P = .079, and A–C P = .235). Of 
note, the frequency of cirrhosis among the patients receiving 
antiviral treatment declined significantly over the years (A: 
80.2%, B: 44.1%, C: 23.2%; A–B P < .001, B–C P < .001, and 
A–C P < .001). In contrast, patients with kidney transplantation 
receiving sirolimus, everolimus, cyclosporine, or tacrolimus 
increased over time (A: 0.0%, B: 2.3%, C: 4.0%; A–C P = .008) 
(Table 1). Although there was no remarkable change in the me-
dian number of drugs over the different time periods (A: 3, B: 3, 
C: 2), we documented a numerical, continuous increase in the 
proportion of patients using ≥8 drugs as outpatient medications 
(A: 11.1%, B: 15.2%, C: 17.2%; A–B P = .231, B–C P = .549, and 
A–C P = .089) (Table 1, Figure 1). In this particular subgroup of 
patients, 32.0% and 9.0% were ≥65 years old and ≥75 years old, 
respectively. The frequency of cirrhosis was 52.0%.
Potential of Different Antiviral Substances to Cause Drug–Drug Interactions
In total, 353 different substances were found in the regular 
outpatient medication of the cohort (Supplementary Table 1). 
In 28 patients (4.2%), some medication could not be clearly 
identified based on the description provided by the patient. 
Pantoprazole (22.0%), levothyroxine (14.4%), and spirono-
lactone (12.3%) were used most frequently. Overall, the top 
most used medications did not change significantly over time 
(Supplementary Table 2).
All outpatient medication was assessed with each individual 
antiviral drug/regimen for potential DDIs that might occur 
in case of coadministration. Among all treatment regimens, 
the combination of OBV/PTV/r and BOC (alone) showed the 
highest potential for DDI (ie, category 2, 3, or 4) with the ana-
lyzed concomitant medication (37.1%), whereas SOF (alone) 
showed the lowest (2.8%). When examining the different time 
periods in detail, it became obvious that in every treatment 
period DAAs with a considerable potential for DDIs were to be 
found. As expected, the first-wave PIs BOC and TVR had much 
higher potential for DDIs, affecting 37.1% and 36.3% of outpa-
tient medications, respectively. In the following period, starting 
with the approval of SOF, the potential for DDIs widely differed 
between the individual drugs that were available. SOF, SIM, and 
DAC showed potential for DDIs with 2.8%, 25.2%, and 12.5% of 
the outpatient medication, respectively. Risk for DDIs increased 
in the era of the first DAA fixed-dose combinations. The IFN-
free regimen OBV/PTV/r ± DSV showed contraindications be-
cause of DDIs (category 4) with 30 drugs from the outpatient 
medications of the patients (8.5%) and potential significant 
DDIs (category 3) with 86 out of 353 drugs (24.4%) (Figure 2; 
Supplementary Table 3).
Compared with previous treatment periods, the current most-
used regimens, GLE/PIB, ELB/GRZ, VEL/SOF ± VOX, did not 
greatly differ in their potential for DDIs. The frequency of po-
tential DDIs with outpatient medications ranged from 12.2% to 
19.8%. Contraindications due to DDIs (category 4) appeared with 
up to 4.5% of the concomitant medications, up to 10.5% of the 
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concomitant medications had a potential significant DDI (category 
3) with the antivirals, and up to 5.1% showed a potential weak DDI 
(category 2). Overall, the potential for DDIs was lower compared 
with most of the older IFN-free regimens (Figure 2).
Among all 353 assessed regular outpatient medications, 
antiepileptic drugs (carbamazepine [5 patients], eslicarbazepine 
[1 patient], and oxcarbazepine [1 patient]), St. John’s wort (1 pa-
tient), and rifampicin (1 patient) were identified as the medica-
tions with the highest potential for DDIs, being contraindicated 
for coadministration with ≥10 of the 14 different antiviral regi-
mens/substances (Supplementary Table 4). The main reason for 
the contraindications was a strong CYP induction by these sub-
stances, which would accelerate the metabolism of the antivirals 
and risk the efficacy of treatment when coadministered.
Real-World Incidence of Drug–Drug Interactions due to Antiviral Treatment
In the second step of our analysis, only the actually received 
HCV therapy and concomitant medications were considered for 
each patient in the assessment of DDIs: Overall, the frequency 
of DDIs in period B (49.6%) was significantly higher compared 
with periods A  (37.1%; P = .012) and C (38.8%; P = .014). 
A  similar picture was documented when exclusively focusing 
on potential significant DDIs (category ≥3). Moreover, the inci-
dence of contraindications because of DDIs (category 4) stayed 
constant over all periods, with a slight increase in period B (A: 
3.7%, B: 4.7%, C: 3.6%; A–B P = .629, B–C P = .540, and A–C 
P = .956) (Figure 3A–C). In the majority of these cases, contra-
indicated concomitant medications were discontinued and/or 
changed to a less interacting alternative. In some patients, med-
ication was continued under individual clinical surveillance 
(Supplementary Table 5).
Patients with cirrhosis and those aged ≥65 years used signifi-
cantly more concomitant medications (mean number of drugs, no 
cirrhosis vs cirrhosis: 3.2 vs 4.3, P < .001; <65 years vs ≥65 years: 
3.4 vs 5.0, P < .001). Both of these subgroups showed an increased 
risk of DDIs (cirrhosis: relative risk [RR], 1.37; 95% confidence in-
terval [CI], 1.14–1.63; age ≥65 years: RR, 1.79; 95% CI, 1.52–2.11). 
Among patients with cirrhosis (n = 301), 42.5% had potential sig-
nificant DDIs (category 3) with the respective DAA therapy, in 
comparison with 28.9% of patients without cirrhosis (P < .001). 
The frequency of contraindicated outpatient medication was 
similar between both groups. Among patients with an age of 
18–64 years (n = 525), 29.0% were at risk for potential significant 
DDIs (category 3), whereas this was the case in 56.6% and 59.1% 
(P < .001) of patients aged 65–74 and ≥75 years, respectively. The 
frequency of contraindicated concomitant medication was also 
higher in those aged ≥65 years (Figure 3D). Another particularly 
vulnerable group for DDIs was patients receiving polypharmacy. 
Overall, 9 out of 10 patients (90.0%) taking ≥8 drugs as outpatient 
medication showed at least 1 DDI (category 2–4) (Figure 3E).
Most Relevant Medications and Pharmacokinetic Mechanisms Involved in 
DDIs With Currently Used DAA Regimens
The most common outpatient medications involved in signif-
icant DDIs (category 3 or 4)  with the most recently approved 
DAA regimens, VEL/SOF (n = 58), GLE/PIB (n = 46), and ELB/
Table 1. Baseline Characteristics of the Cohort
Total Cohort Jan 2014–Nov 2014 Nov 2014–Aug 2016 Aug 2016–Jul 2018 
No. of patients (%) 668 (100.0) 162 (24.3) 256 (38.3) 250 (37.4)
Sex, No. (%)     
Female 301 (45.1) 65 (40.1) 122 (47.7) 114 (45.6)
Male 367 (54.9) 97 (59.9) 134 (52.3) 136 (54.4)
Age, mean (range), y 55.5 (18–85) 
[6.6% ≥75 y]
55.3 (24–81)  
[3.1% ≥75 y]
58.2 (24–85)  
[9.8% ≥75 y]
52.9 (18–82) 
[5.6% ≥75 y]
Cirrhosis, No. (%) 301 (45.1) 130 (80.2) 113 (44.1) 58 (23.2)
Child A 247 (82.1) 108 (83.1) 94 (83.2) 45 (77.6)
Child B 38 (12.6) 19 (14.6) 10 (8.8) 9 (15.5)
Child C 5 (1.7) 2 (1.5) 3 (2.7) 0 (0)
N/A 11 (3.7) 1 (0.8) 6 (5.3) 4 (6.9)
HCV genotype, No. (%)     
1 477 (71.4) 101 (62.3) 217 (84.8) 159 (63.6)
2 29 (4.3) 13 (8.0) 2 (0.8) 14 (5.6)
3 123 (18.4) 42 (25.9) 23 (9.0) 58 (23.2)
4 22 (3.3) 4 (2.5) 7 (2.7) 11 (4.4)
5 7 (1.0) 1 (0.6) 2 (0.8) 4 (1.6)
6 1 (0.1) 0 (0) 0 (0) 1 (0.4)
N/A 9 (1.3) 1 (0.6) 5 (2.0) 3 (1.2)
No. outpatient medications, median (range) 3 (0–19) 3 (0–18) 3 (0–16) 2 (0–19)
Kidney transplant patients receiving sirolimus, 
everolimus, cyclosporine, or tacrolimus
16 (2.4) 0 (0) 6 (2.3) 10 (4.0)
Abbreviations: HCV, hepatitis C virus; N/A, not available.
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GRZ (n = 73), were proton pump inhibitors (PPIs), metamizole, 
statins, and carvedilol (Supplementary Table 6). More precise in-
formation on relevant DDIs and their respective mechanisms can 
be found in the Supplementary Data (Supplementary Table 7).
DDIs between regular outpatient medications and specific 
antiviral regimens were not uniform, but were dependent on 
the possible interaction mechanisms of each antiviral reg-
imen and the concomitant medication. Overall, compared 
with the older regimens, interactions with the most modern 
DAAs were less frequently caused by CYP and P-gp pathways 
(Figure 4). GLE/PIB (n = 46) DDIs were distributed between 
DDIs facilitated by organic anion transporting protein (OATP; 
23.5%), pH-change (15.7%), P-gp (27.5%), and the CYP path-
ways (27.5%). ELB/GRZ (n = 73) interactions were mediated 
via CYP enzymes (49.0%) and breast cancer resistance protein 
(BCRP; 27.5%) most of the time. This was mainly caused by 
interactions with statins. Some statins are metabolized by CYP 
enzymes and may also be transported via OATP1B1/3 and/or 
BCRP. ELB/GRZ is a weak CYP 3A inhibitor in vivo and blocks 
intestinal BCRP. Concomitant use may cause higher statin 
blood levels, and the risk for adverse events like rhabdomyol-
ysis increases. In contrast to that, VEL/SOF ± VOX (without 
VOX: n = 58; with VOX: n = 9) interactions, in >50% of cases 
(VEL/SOF: 56.8%; VEL/SOF + VOX: 60.0%), were due to a PPI 
increasing gastric pH, thereby causing lower absorption rates 
of mainly VEL. DDIs between regular outpatient medications 
and VEL/SOF ± VOX via BCRP (6.8%; with VOX: 20.0%), 
P-gp (15.9%; with VOX: 0.0%), and CYP enzymes (20.5%; with 
VOX: 20.0%) also occurred but were represented less in this 
part of the cohort (Figure 4; Supplementary Table 8).
DISCUSSION
In the PEG-IFN α/RBV era, DDIs were of little concern. DDIs 
mainly emerged as a new challenge with the approval of DAAs 
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for the treatment of HCV infection [11]. Although this work 
for the first time provides extensive data on DDIs with the most 
recent DAA regimens, it also allows a detailed comparison be-
tween each step of HCV therapy evolution over the last years. 
We here show that the different DAA regimens that were used 
over the last decade widely differ in their general potential to 
cause DDIs with the outpatient medications of HCV patients. 
Currently, the most widely used DAAs demonstrate a moderate 
DDI risk profile, which is significantly lower compared with 
first-generation PIs used from 2011 or the combinations with 
ritonavir booster used from 2014 [10, 20]. However, our work 
also demonstrates that despite these advantages, the overall fre-
quency of DDIs in the real-world analysis remained more or less 
stable over the treatment periods, with about 40% of HCV pa-
tients affected. Advantages in HCV therapy were accompanied 
by a change in the epidemiology of HCV patients, mainly due 
to treatment eligibility and expansion [1, 14, 33]. Some of these 
changes (ie, higher frequency of polypharmacy) at least partly 
counteracted the lower potential risk for DDI with the newer 
DAA regimens. Thus, we conclude that DDIs remain relevant, 
should not be underestimated, and still need to be considered in 
the management of HCV patients.
Our analysis demonstrates that HCV patients’ characteristics 
have indeed changed during the different treatment periods. 
The frequency of treated patients with cirrhosis has significantly 
decreased. In addition, the mean age of the patients decreased, 
but, importantly, the proportion of patients aged ≥75 years or/
and with polypharmacy increased. One may assume that this is 
a result of treatment policy over the last years. Patients with ad-
vanced stages of liver disease were treated first at our and several 
other centers [7, 14, 34]. Many of these patients were infected 
before the introduction of anti-HCV testing in the early 1990s. 
However, the most complicated cases (ie, severe contraindica-
tions, decompensated cirrhosis, and renal impairment) or those 
without advanced disease, and in particular those with older 
age, were frequently deferred [7, 14]. As a result, the overall 
HCV population we are now facing in HCV therapy has been 
getting younger (lower likelihood for advanced liver disease). 
However, at the same time, the proportion of the subgroup of 
highly complicated patients (eg, old age, polypharmacy) has 
been increasing, as modern DAA regimens have significantly 
improved on safety and efficacy in this group [21, 26, 35–37]. 
Putting the focus for example on immunosuppressive drugs, we 
recorded a significant increase due to new treatment options 
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Figure 2. Possible drug–drug interactions with all outpatient medications from the cohort. Abbreviation: PEG-IFN, pegylated interferon.
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for renal transplant recipients (ie, glecaprevir/pibrentasvir and 
elbasvir/grazoprevir). The excellent treatment options avail-
able started an intensive debate about the use of HCV-positive 
donor organs for HCV-negative recipients. It seems likely that 
the treatment of transplant recipients may remain particularly 
relevant in the near future [38]. These patients often receive 
highly complex polypharmacy with the immunosuppressive 
drugs (ie, sirolimus, everolimus, cyclosporine, or tacrolimus) 
themselves being potential partners for relevant DDIs [39].
Changes in the epidemiology of the HCV population might 
furthermore affect the frequency of the most relevant mechan-
isms of DDIs. Additionally, the individual chemical and phar-
macokinetic characteristics of each DAA play a substantial role 
as well. Indeed, the present work emphasizes that the pathways 
involved in DDIs in the real world are distinct for each regimen. 
Statins interact more frequently with ELB/GRZ, and VEL-
containing regimens show a majority of DDIs via pH elevation 
in the stomach. When looking at the newer, mainly PPI-caused 
mechanisms, certainly more data are needed [40]. Due to the 
variety of DAAs available, DDI assessment has become more 
complex.
Individualized management, especially in complex patients, 
remains highly important. However, it also has to be noted that 
strict contraindications due to DDIs were quite rare when using 
modern DAAs and the remaining significant DDIs seemed very 
manageable by dose modifications or monitoring interventions. 
First of all, awareness of DDIs still represents the most impor-
tant step. Tools like www.hep-druginteractions.org provide the 
involved health care professionals with reliable resources to 
identify and handle potential DDIs.
The present work has some limitations. First, it is a single-
center analysis from a tertiary referral center. Thus, a higher 
frequency of patients with more advanced liver disease is likely, 
as indicated by the higher-than-average rate of patients with cir-
rhosis. However, it should be noted that it was not patients with 
cirrhosis but rather elderly patients who showed a comparably 
higher risk for DDIs, as shown in our analysis and as previously 
reported [21]. Second, with the restrictions for elderly patients 
for clinical trials and the low likelihood for liver transplantation, 
we would not expect that elderly patients were over-represented 
in our institution. The same affects patients with current intra-
venous drug use (PWID). For PWID, we would rather quote 
that they were under-represented due to the fact that active 
drug users are more frequently treated at other centers. Third, 
under-reporting of concomitant medication and nonadherence 
to recommendations on DDI management cannot be excluded, 
as the collection of medication data was based on patient 
self-report and letters of referral from physicians. Additionally, 
physicians may have changed the concomitant medication in 
anticipation of antiviral therapy. Therefore, we tracked changes 
to the concomitant medication back before initiation of anti-
viral therapy to include any changes due to suspected DDI.
Further research on DDIs in HCV therapy will be required 
to ensure a safe upscaling of HCV treatments, which is essen-
tial to meet World Health Organization goals and ultimately 
achieve HCV elimination. The HCV population will certainly 
see further changes over the next years that will affect the risk 
for DDIs, as well as the most relevant drugs and mechanisms 
involved. Unrestricted treatment of high-risk populations like 
PWID will require general considerations and strategies for 
how to handle the most relevant potential DDIs in this specific 
group, as adequate monitoring during therapy might not always 
be possible.
To our knowledge, this is the first work that assesses the risk 
of DDIs with various regimens in various time periods and also 
the first that considers the most recent DAA regimens as well 
as relevant DDI mechanisms. It shows that despite improved 
newer antiviral regimens, the frequency of significant real-
world DDIs in a changing epidemiology of HCV patients has 
not declined, but remained stable. Therefore, careful assessment 
of patients’ regular outpatient medications and individual eval-
uation for potential DDIs seem as important as ever.
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